Articles tagged "Calcineurin"

2020 American Transplant Congress
Sirolimus Combined with Low-Dose Calcineurin Inhibitor in Kidney Transplant Recipients from Expanded Criteria Donors
J. Zhang, J. Lin, Y. Tian, W. Sun, L. Zhang
Beijing Friendship Hospital, Capital Medical University, Beijing, China
*Purpose: To evaluate the efficacy and safety of conversion from calcineurin inhibitor-based immunosuppressive regimen to sirolimus combined with low-dose calcineurin inhibitor in recipients with abnormal…
2020 American Transplant Congress
Prospective Donor-Specific CellUlar Alloresponse Assessment for Immunosuppression MinImization in De Novo Renal Transplantation: Results of a Randomized Controlled Biomarker-Guided Trial
O. Bestard¹, P. Reinke², F. Bemelman³, O. Viklicky⁴, M. Koch⁵, M. Giral⁶, J. Ruiz⁷, B. Banas⁸, E. Crespo¹, M. Meneghini¹, H. Volk⁹, J. Grinyo¹
¹Kidney transplantation Unit, Bellvitge University Hospital- IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain, ²Kidney transplantation Unit, Charité - Universitätsmedizin Berlin, Berlin, Germany, ³Kidney transplantation Unit, Amsterdam Medical Centre, Amsterdam, Netherlands, ⁴Nephrology department, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic, ⁵Department of Hepatobiliary Surgery and Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁶Nephrology, Kidney transplantation Unit, Université de Nantes, Nantes, France, ⁷Nephrology, Hospital Marques de Valdecilla, Santander, Spain, ⁸Kidney transplantation Unit, University Hospital Regensburg, Regensburg, Germany, ⁹Institute for Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
*Purpose: Early immunosuppression minimization is associated with higher rates of BPAR. Preformed donor-specific T-cell alloreactivity (DST) assessed with an IFN-γ ELISPOT assay has shown to…
2020 American Transplant Congress
Early Tacrolimus-LCP Conversion Due to Adverse Effects in Pancreas Transplant Recipients Improves Tolerance But Not Graft Survival
J. L. Descourouez, M. R. Jorgenson, D. C. Felix, J. Wiegel, G. E. Leverson, D. A. Mandelbrot, R. R. Redfield, J. S. Odorico
UW Health, Madison, WI
*Purpose: Tacrolimus-LCP (LCPT) is an extended release formulation of tacrolimus which has been shown to have fewer adverse drug effects (ADE) than immediate release tacrolimus…
2020 American Transplant Congress
MTOR-Inhibitor Regimens and Malignancy after Kidney Transplantation: Can the Risk Be Modified by Considering Human Leukocyte Antigen (HLA) Mismatch in Immunosuppression Selection?
A. Santos¹, C. Chen¹, K. Alquadan², M. A. Leghrouz², X. Wen³
¹University of Florida, Gainesville, FL, ²Division of Nephrology, Hypertension, & Renal Transplantation, University of Florida, Gainesville, FL, ³Department of Pharmacy Practice, University of Rhode Island, Kingston, RI
*Purpose: We investigated the outcomes of mammalian target of rapamycin inhibitor (MTORI) regimens in adult kidney transplant (KT) recipients (KTRs) in categories of donor/recipient pre-transplant…
2020 American Transplant Congress
Steroids Ameriplate the Progression of Calcineurin Inhibitors Nephrotoxicity in Kidney Allografts
N. Iwahara¹, H. Sasaki², D. Iwami¹, K. Hotta¹, Y. Takada¹, H. Higuchi², T. Tanabe², N. Shinohara¹
¹Hokkaido University, Sapporo, Japan, ²Sapporo City General Hospital, Sapporo, Japan
*Purpose: Although calcineurin inhibitors (CNI) lead to excellent short-term kidney allograft outcome, chronic nephrotoxicity is a major concern which affects long-term allograft survival. It has…
2020 American Transplant Congress
Impact of CYP3A5 Phenotype on Early Time in Therapeutic Range among Pediatric Renal and Heart Transplant Recipients
A. Leino, A. Pasternak
University of Michigan, Ann Arbor, MI
*Purpose: Tacrolimus time in therapeutic range (TTR) as a measure of intra-patient variability has been associated with poor long-term outcomes. Multiple factors may contribute to…
2020 American Transplant Congress
Impact of a Pharmacist Led Outpatient Tacrolimus Monitoring Protocol in Renal Transplant Recipients
K. L. Owen, M. Palettas, H. Winters, T. E. Pesavento, A. Rajab, O. Witkowsky
Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: The purpose of this study is to compare the time within therapeutic range (TTR) of tacrolimus (TAC) before and after the initiation of a…
2020 American Transplant Congress
Comparing Weight-Based Dosing of Envarsus XR in Obese and Non-Obese Renal Transplant Recipients
N. Breslin, N. Jandovitz, V. Nair, M. Abate, L. Teperman
North Shore University Hospital, Manhasset, NY
*Purpose: Tacrolimus has a narrow therapeutic window and significant inter- and intra-patient variability leading to variations in drug concentration. The recommended initial weight-based dose of…
2020 American Transplant Congress
Impact of Concentrations on Conversion from Twice‑Daily to Once‑Daily Tacrolimus in Stable Kidney Graft Recipients: A Single-Center Retrospective Study
Z. Wang, Y. Cao, Y. Fu
Transplant Surgery, Tianjin First Central Hospital, Tian Jin, China
*Purpose: Potential benefits of once-daily tacrolimus include improved adherence to immunosuppressives and decreased Intrapatient variability (IPV) post kidney transplantation. A retrospective analysis was performed to…
2020 American Transplant Congress
Pharmacokinetic Evaluation of a De Novo Envarsus XR® (tacrolimus Extended Release) Dosing Strategy in Kidney Transplant Recipients
J. Schulte¹, C. Kane¹, K. Cunningham¹, C. D'Agostino¹, M. Kapugi¹, A. Novak¹, A. Shetty², J. Leventhal², J. Friedewald²
¹Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ²Division of Transplantation, Northwestern Memorial Hospital, Chicago, IL
*Purpose: Envarsus XR® is a once-daily tablet formulation of tacrolimus recently approved for the prophylaxis of organ rejection in de novo kidney transplant recipients (KTx).…